|
Jan 4
|
CytoSorbents reported strong Q4 results, says D. Boral Capital
|
|
Jan 3
|
CTSO: CytoSorbents Reports Preliminary 4th Quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations.
|
|
Jan 3
|
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
|
|
Oct 9
|
CytoSorbents Corp (CTSO) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
|
|
Oct 1
|
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
|
|
Sep 30
|
Cytosorbents (NASDAQ:CTSO) shareholders have endured a 81% loss from investing in the stock three years ago
|
|
Aug 27
|
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
|
|
Jul 29
|
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
|
|
Jun 24
|
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
|
|
Jun 13
|
CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
|
|
May 15
|
CTSO: CytoSorbents Potential for High Margin Revenue Growth Supports Price Target of $4.00
|
|
May 12
|
Cytosorbents First Quarter 2024 Earnings: In Line With Expectations
|
|
May 10
|
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2024 Earnings Call Transcript
|
|
May 9
|
CytoSorbents Reports First Quarter 2024 Results
|
|
May 2
|
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
|
|
Apr 26
|
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
|
|
Apr 17
|
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
|
|
Apr 4
|
CTSO: CytoSorbents Expects Significant Gross Margin Expansion in 2024.
|
|
Mar 20
|
These Analysts Think Cytosorbents Corporation's (NASDAQ:CTSO) Sales Are Under Threat
|
|
Mar 16
|
Cytosorbents Full Year 2023 Earnings: Misses Expectations
|